JP2000517418A - 定量的関節炎状態のアッセイ - Google Patents
定量的関節炎状態のアッセイInfo
- Publication number
- JP2000517418A JP2000517418A JP10509376A JP50937698A JP2000517418A JP 2000517418 A JP2000517418 A JP 2000517418A JP 10509376 A JP10509376 A JP 10509376A JP 50937698 A JP50937698 A JP 50937698A JP 2000517418 A JP2000517418 A JP 2000517418A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- assay
- comp
- adp
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003556 assay Methods 0.000 title claims abstract description 66
- 206010003246 arthritis Diseases 0.000 title claims abstract description 44
- 210000001124 body fluid Anatomy 0.000 claims abstract description 63
- 239000010839 body fluid Substances 0.000 claims abstract description 59
- 239000007857 degradation product Substances 0.000 claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 26
- 230000002917 arthritic effect Effects 0.000 claims abstract description 18
- 210000001179 synovial fluid Anatomy 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 claims description 37
- 239000003638 chemical reducing agent Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 238000005259 measurement Methods 0.000 claims description 25
- 238000002965 ELISA Methods 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 21
- 210000004899 c-terminal region Anatomy 0.000 claims description 17
- 238000001262 western blot Methods 0.000 claims description 15
- 238000011534 incubation Methods 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 11
- 238000001962 electrophoresis Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 9
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 8
- 101000725508 Homo sapiens Cartilage oligomeric matrix protein Proteins 0.000 claims description 6
- 102000050578 human COMP Human genes 0.000 claims description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 5
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 5
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 claims 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 79
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 23
- 108060008245 Thrombospondin Proteins 0.000 abstract description 6
- 102000002938 Thrombospondin Human genes 0.000 abstract description 5
- 201000008482 osteoarthritis Diseases 0.000 description 23
- 206010039073 rheumatoid arthritis Diseases 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 210000000845 cartilage Anatomy 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 102100036034 Thrombospondin-1 Human genes 0.000 description 10
- 108010046722 Thrombospondin 1 Proteins 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 229920001220 nitrocellulos Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 239000000020 Nitrocellulose Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- 230000002788 anti-peptide Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012286 ELISA Assay Methods 0.000 description 5
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 241000219061 Rheum Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 102000055008 Matrilin Proteins Human genes 0.000 description 4
- 108010072582 Matrilin Proteins Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000013024 dilution buffer Substances 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000016284 Aggrecans Human genes 0.000 description 3
- 108010067219 Aggrecans Proteins 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 241000906034 Orthops Species 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000002456 anti-arthritic effect Effects 0.000 description 3
- 230000008355 cartilage degradation Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 2
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000003042 chondroprotective agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 206010071155 Autoimmune arthritis Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000001148 Cartilage Fractures Diseases 0.000 description 1
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101000725512 Rattus norvegicus Cartilage oligomeric matrix protein Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940124347 antiarthritic drug Drugs 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- JQQZVABVKIDEFR-UHFFFAOYSA-J bumadizone calcium hemihydrate Chemical compound O.[Ca+2].[Ca+2].C=1C=CC=CC=1N(C(=O)C(C([O-])=O)CCCC)NC1=CC=CC=C1.C=1C=CC=CC=1N(C(=O)C(C([O-])=O)CCCC)NC1=CC=CC=C1.C=1C=CC=CC=1N(C(=O)C(C([O-])=O)CCCC)NC1=CC=CC=C1.C=1C=CC=CC=1N(C(=O)C(C([O-])=O)CCCC)NC1=CC=CC=C1 JQQZVABVKIDEFR-UHFFFAOYSA-J 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 230000003011 chondroprotective effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010074709 ronidase Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. (1)関節炎患者から得た体液サンプルの還元または非還元条件下でのインキュベ ート; (2)体液サンプルと抗−ADP抗体とのインキュベート;そして (3)体液サンプル中の結合抗−ADP抗体のレベルの測定 を含むADPのレベルの測定のためのアッセイ。 2.体液サンプルが血清および滑液からなる群から選択される、請求項1記載 のアッセイ。 3.滑液を更に粘性減少剤で処理する、請求項2記載のアッセイ。 4.抗−ADP抗体がペプチドH741およびペプチドHrat、ペプチドHbovお よびペプチドH669からなる群から選択される合成ペプチドに対する抗体であ る、請求項2記載のアッセイ。 5.抗−ADP抗体が抗体H741である、請求項4記載のアッセイ。 6.体液サンプル中の結合抗−ADP抗体のレベルの測定法がELISAであ る、請求項2記載のアッセイ。 7. (1)関節炎患者から得た体液サンプルの還元または非還元条件下でのインキュベ ート; (2)体液サンプルと、抗体H741および抗体Hrat、抗体Hbovおよび抗体H66 9からなる群から選択される抗−ADP抗体とのインキュベート;そして (3)体液サンプル中の結合抗−ADP抗体のレベルのELISAによる測定 を含むADPのレベルの測定のためのアッセイ。 8. (1)関節炎患者から得た体液サンプルの還元条件下でのインキュベート; (2)体液サンプルと抗−ADP抗体とのインキュベート;そして (3)体液サンプル中の結合抗−ADP抗体のレベルの測定 を含むADPのレベルの測定のためのアッセイ。 9.体液サンプルが血清および滑液からなる群から選択される、請求項8記載 のアッセイ。 10.滑液を更に粘性減少剤で処理する、請求項9記載のアッセイ。 11.還元条件がジチオスレイトールおよびメルカプトエタノールからなる群 から選択される還元剤の溶液である、請求項9記載のアッセイ。 12.還元剤がジチオスレイトールの溶液である、請求項11記載のアッセイ 。 13.還元条件が0.1−100mMの濃度のジチオスレイトールの溶液であ る、請求項12記載のアッセイ。 14.還元条件が0.1mMの濃度のジチオスレイトールの溶液、約30秒か ら約30分、約25−45℃である、請求項12記載のアッセイ。 15.還元条件が0.1mMの濃度のジチオスレイトールの溶液、約5分、約 37℃である、請求項14記載のアッセイ。 16.体液を更にLMW-COMPを分離するための分離法に付す、請求項11記載の アッセイ。 17.分離法がSDS−PAGE電気泳動である、請求項16記載のアッセイ 。 18.抗−ADP抗体がペプチドH741およびペプチドHrat、ペプチドHbov およびペプチドH669からなる群から選択される合成ペプチドに対する抗体で ある、請求項9記載のアッセイ。 19.抗−ADP抗体が抗体H741である、請求項18記載のアッセイ。 20.体液サンプル中の抗−ADP抗体のレベルの測定法がウエスタンブロッ ティングまたはELISAである、請求項9記載の方法。 21.体液を工程(3)の前に還元剤不活性化物質にさらす、請求項20記載の アッセイ。 22.体液サンプル中の抗−ADP抗体のレベルの測定法がウエスタンブロッ ティングである、請求項21記載の方法。 23. (1)関節炎患者から得た体液サンプルの、0.1−100mMの濃度のジチオス レイトールの溶液、約30秒から約30分、約25℃−45℃である還元条件下 でのインキュベート; (2)体液サンプルと、抗体H741および抗体Hrat、抗体Hbovおよび抗体H66 9からなる群から選択される抗−ADP抗体とのインキュベート;そして (3)ウエスタンブロッティングまたはELISAによる体液サンプル中の結合抗 −ADP抗体のレベルの測定(ウエスタンブロッティングは電気泳動後に行う) を含むADPのレベルの測定のためのアッセイ。 24.体液を工程(2)の前に還元剤不活性化物質にさらす、請求項23記載の アッセイ。 25.14,000ダルトンから33,000ダルトンの分子量を有し、抗−A DP抗体により認識されるタンパク質を含む、単離LMW-C0MPタンパク質。 26.LMW-COMP抗体がヒトCOMPのC−末端へプタデカペプチドに対する抗 体である、請求項25記載の単離LMW-COMPタンパク質。 27.タンパク質がPAGEで約20,000の分子量を有する、請求項25 記載のLMW-COMPタンパク質。 28.抗−ADP抗体が抗体H741および抗体Hrat、抗体Hbovおよび抗体H 669からなる群から選択される、請求項25記載の単離LMW-COMPタンパク質。 29.抗−ADP抗体が抗体H741および抗体Hrat、抗体Hbovおよび抗体H 669からなる群から選択される、請求項28記載の単離LMW-COMPタンパク質。 30.約20,000の見かけの分子量を有するLMW-COMPに結合する。抗体。 31.抗体H741および抗体Hrat、抗体Hbovおよび抗体H669からなる群 から選択される、請求項30記載の抗体。 32.抗体がモノクローナル抗体である、請求項31記載の抗体。 33.分子量約14から約33キロダルトンのLMW-COMPの溶液を含む、体液サ ンプル中のLMW-COMPのレベルの測定用キット。 34.抗−ADP抗体を更に含む、請求項33記載のキット。 35. (1)請求項1に従った、関節炎患者由来の体液サンプル中のLMW-COMP分解産物の レベルの測定; (2)体液サンプル中のKSのレベルの測定;そして (3)LMW-COMP対KSの比率の測定 を含む、LMW-COMP分解産物対KSの比率の測定のアッセイ。 36. (1)請求項7に従った、関節炎患者由来の体液サンプル中のLMW-COMP分解産物の レベルの測定; (2)体液サンプル中のKSのレベルの測定;そして (3)LMW-COMP対KSの比率の測定 を含む、LMW-COMP分解産物対KSの比率の測定のアッセイ。 37. (1)請求項8に従った、関節炎患者由来の体液サンプル中のLMW-COMP分解産物の レベルの測定; (2)体液サンプル中のKSのレベルの測定;そして (3)LMW-COMP対KSの比率の測定 を含む、LMW-COMP分解産物対KSの比率の測定のアッセイ。 38. (1)請求項23に従った、関節炎患者由来の体液サンプル中のLMW-C0MP分解産物 のレベルの測定; (2)体液サンプル中のKSのレベルの測定;そして (3)LMW-COMP対KSの比率の測定 を含む、LMW-COMP分解産物対KSの比率の測定のアッセイ。 39. (1)請求項34に従った、関節炎患者由来の体液サンプル中のLMW-COMP分解産物 のレベルの測定; (2)体液サンプル中のKSのレベルの測定;そして (3)LW-COMP対KSの比率の測定 を含む、LMW-COMP分解産物対KSの比率の測定のアッセイ。 40.抗−ADP抗体がペプチドH741およびペプチドHrat、ペプチドHbov およびペプチドH669からなる群から選択される合成ペプチドに対する抗体で ある、請求項35記載のアッセイ。 41.抗−ADP抗体がペプチドH741およびペプチドHrat、ペプチドHbov およびペプチドH669からなる群から選択される合成ペプチドに対する抗体で ある、請求項36記載のアッセイ。 42.抗−ADP抗体がペプチドH741およびペプチドHrat、ペプチドHbov およびペプチドH669からなる群から選択される合成ペプチドに対する抗体で ある、請求項37記載のアッセイ。 43.抗−ADP抗体がペプチドH741およびペプチドHrat、ペプチドHbov およびペプチドH669からなる群から選択される合成ペプチドに対する抗体で ある、請求項38記載のアッセイ。 44.抗−ADP抗体がペプチドH741およびペプチドHrat、ペプチドHbov およびペプチドH669からなる群から選択される合成ペプチドに対する抗体で ある、請求項39記載のアッセイ。 45.請求項1に従ったADPの測定を含む、哺乳類における関節炎状態の存 在および/または進行の診断法。 46.請求項7に従ったADPの測定を含む、哺乳類における関節炎状態の存 在および/または進行の診断法。 47.請求項8に従ったADPの測定を含む、哺乳類における関節炎状態の存 在および/または進行の診断法。 48.請求項23に従ったADPの測定を含む、哺乳類における関節炎状態の 存在および/または進行の診断法。 49.請求項34に従ったADPの測定を含む、哺乳類における関節炎状態の 存在および/または進行の診断法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2404196P | 1996-08-15 | 1996-08-15 | |
US60/024,041 | 1996-08-15 | ||
PCT/EP1997/004316 WO1998007035A1 (en) | 1996-08-15 | 1997-08-08 | Assay for quantifying arthritic conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000517418A true JP2000517418A (ja) | 2000-12-26 |
JP4189033B2 JP4189033B2 (ja) | 2008-12-03 |
Family
ID=21818539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50937698A Expired - Fee Related JP4189033B2 (ja) | 1996-08-15 | 1997-08-08 | 定量的関節炎状態のアッセイ |
Country Status (7)
Country | Link |
---|---|
US (1) | US6589755B1 (ja) |
EP (1) | EP0922225B1 (ja) |
JP (1) | JP4189033B2 (ja) |
AT (1) | ATE259505T1 (ja) |
AU (1) | AU4298297A (ja) |
DE (1) | DE69727582T2 (ja) |
WO (1) | WO1998007035A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003087820A1 (fr) * | 2002-04-16 | 2003-10-23 | Riken | Procede d'etude de la defaillance de la proteine comp |
JP2010530972A (ja) * | 2007-06-20 | 2010-09-16 | シェーリング コーポレイション | 炎症性関節疾患に対する抗il−17a治療のための関節破壊のバイオマーカー |
JP2015522817A (ja) * | 2012-06-28 | 2015-08-06 | アナマー エービー | 病的な軟骨代謝回転の決定 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2788603B1 (fr) * | 1999-01-20 | 2001-04-13 | Covalab | PROCEDE D'IMMUNOANALYSE D'UNE PROTEINE MATRICIELLE OLIGOMERIQUE DU CARTILAGE -comp-, SONDE ANTIGENIQUE, ANTICORPS ET NECESSAIRE D'IMMUNOANALYSE UTILISE POUR LA MISE EN OEUVRE DE CE PROCEDE |
US6849594B1 (en) | 1999-06-30 | 2005-02-01 | John Lawler | Purification and use of human recombinant cartilage oligomeric matrix protein |
SE9904236D0 (sv) * | 1999-11-22 | 1999-11-22 | Ana Mar Diagnostics Ab | Immunoassay |
US20030119074A1 (en) * | 2001-12-20 | 2003-06-26 | George Jackowski | Diagnosis and treatment of dementia utilizing thrombospondin |
US7655411B2 (en) * | 2002-08-23 | 2010-02-02 | W2 Holdings, Inc. | Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer |
DE602005026525D1 (de) * | 2004-05-24 | 2011-04-07 | Anamar Ab | Verfahren zur bestimmung eines gewebeabbauverfahrens durch nachweis von comp-neoepitopen |
EP1805513A4 (en) * | 2004-10-20 | 2009-06-10 | Onco Detectors International L | FACTOR FOR INHIBITING MIGRATION OF MACROPHAGES IN THE SERUM AS A TUMOR MARKER FOR PROSTATE, BLADDER, BREAST, OVARY, KIDNEY AND LUNG CANCER |
EP3015069A1 (en) | 2014-10-30 | 2016-05-04 | Universitätsklinikum Jena | Apparatus for suspended ultrasonography and corresponding method |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8304836D0 (sv) | 1983-09-09 | 1983-09-09 | Pharmacia Ab | Sett att bestemma forendringar i ledbrosk |
US4610960A (en) * | 1983-12-21 | 1986-09-09 | Wisconsin Alumni Research Foundation | Monoclonal antibody to thrombospondin and method for assaying for and isolating thrombospondin |
JP3694894B2 (ja) * | 1994-02-19 | 2005-09-14 | 生化学工業株式会社 | 正常アグリカンの測定法および測定用キット |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
AUPM666894A0 (en) | 1994-07-07 | 1994-07-28 | University Of Melbourne, The | Diagnostic methods and compositions |
-
1997
- 1997-08-08 DE DE69727582T patent/DE69727582T2/de not_active Expired - Fee Related
- 1997-08-08 JP JP50937698A patent/JP4189033B2/ja not_active Expired - Fee Related
- 1997-08-08 EP EP97918970A patent/EP0922225B1/en not_active Expired - Lifetime
- 1997-08-08 AU AU42982/97A patent/AU4298297A/en not_active Abandoned
- 1997-08-08 US US09/242,427 patent/US6589755B1/en not_active Expired - Fee Related
- 1997-08-08 AT AT97918970T patent/ATE259505T1/de not_active IP Right Cessation
- 1997-08-08 WO PCT/EP1997/004316 patent/WO1998007035A1/en active IP Right Grant
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003087820A1 (fr) * | 2002-04-16 | 2003-10-23 | Riken | Procede d'etude de la defaillance de la proteine comp |
JP2010530972A (ja) * | 2007-06-20 | 2010-09-16 | シェーリング コーポレイション | 炎症性関節疾患に対する抗il−17a治療のための関節破壊のバイオマーカー |
JP2015522817A (ja) * | 2012-06-28 | 2015-08-06 | アナマー エービー | 病的な軟骨代謝回転の決定 |
Also Published As
Publication number | Publication date |
---|---|
EP0922225A1 (en) | 1999-06-16 |
DE69727582D1 (de) | 2004-03-18 |
EP0922225B1 (en) | 2004-02-11 |
JP4189033B2 (ja) | 2008-12-03 |
DE69727582T2 (de) | 2004-12-23 |
ATE259505T1 (de) | 2004-02-15 |
WO1998007035A1 (en) | 1998-02-19 |
AU4298297A (en) | 1998-03-06 |
US6589755B1 (en) | 2003-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0742902B1 (en) | A method of assaying collagen fragments in body fluids, a test kit and means for carrying out the method and use of the method to diagnose the presence of disorders associated with the metabolism of collagen | |
Saxne et al. | Increased release of bone sialoprotein into synovial fluid reflects tissue destruction in rheumatoid arthritis | |
JPH08501151A (ja) | 敗血症の早期検出、重篤度測定、および治療に伴なう敗血症経過の評価のための方法、ならびにその方法の実施手段 | |
JP4268684B2 (ja) | 骨代謝異常症の診断方法 | |
US6342361B1 (en) | Method of assaying collagen fragments in body fluids, a test kit and means for carrying out the same | |
JP2000517418A (ja) | 定量的関節炎状態のアッセイ | |
JP3913787B2 (ja) | I型コラーゲン断片のサンドウイッチ測定法 | |
JP2000516721A (ja) | 体液中のd―アミノ酸の測定法 | |
US20090291462A1 (en) | Detection or Quantification of Aggrecan and its Fragments | |
EP0960339A1 (en) | Assay for collagen type ii fragments | |
US8663944B2 (en) | Cartilage intermediate layer protein 2 C1 and its use to differentiate osteoarthritis from rheumatoid arthritis and non-disease conditions | |
JPH10507266A (ja) | 体液中のコラーゲンの断片化パターンの評価とコラーゲンの代謝に関連する疾患の診断 | |
JP2837872B2 (ja) | 腫瘍診断法 | |
JP4414023B2 (ja) | 関節炎関連メラノトランスフェリンの測定方法および試薬 | |
US20040132064A1 (en) | Ratios of collagen peptides, their uses and products | |
EP1415163B1 (en) | Assay of isomerised and/or optically inverted proteins and protein fragments | |
Jäälinoja et al. | Serum antibodies against intact human collagen IX are elevated at onset of rheumatoid arthritis but are not related to development of erosions. | |
JP4527286B2 (ja) | サンプル中のS100αβおよびS100ββの総量を定量する方法、サンプル中のS100ββの量を定量する方法、サンプル中のS100αβの量を定量する方法、S100ββの量をアッセイするためのキット、S100αβの量をアッセイするためのキット、ハイブリドーマ細胞系S10:3、ハイブリドーマ細胞系S35:2、及びハイブリドーマ細胞系S23:2 | |
US20080241945A1 (en) | Peptide for differentiating osteoarthritis from rheumatoid arthritis and non-disease conditions | |
JPH06194367A (ja) | リウマチ疾患の診断方法 | |
EP1232396A2 (en) | Assay of isomerised and/or optically inverted proteins | |
FR2865034A1 (fr) | Procede d'evaluation de la degradation du tissu cartilagineux d'un individu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070925 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20071225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080902 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080912 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110919 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110919 Year of fee payment: 3 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
LAPS | Cancellation because of no payment of annual fees |